DNAPrint Working Capital from 2010 to 2026
DNAPrint Genomics' Working Capital is steady over the last several years with stable swings. Working Capital is predicted to flatten to 0.00. Working Capital is the difference between a company's current assets and current liabilities, indicating the liquidity and operational efficiency of the business. View All Fundamentals
Check out the analysis of DNAPrint Genomics Correlation against competitors. For more detail on how to invest in DNAPrint Stock please use our How to Invest in DNAPrint Genomics guide.
Working Capital | First Reported 2010-12-31 | Previous Quarter 0.0 | Current Value 0.0 | Quarterly Volatility 0.0 |
Check DNAPrint Genomics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among DNAPrint Genomics' main balance sheet or income statement drivers, such as Interest Expense of 0.0, Selling General Administrative of 2.8 M or Total Revenue of 2.9 M, as well as many indicators such as Price To Sales Ratio of 1.49, Dividend Yield of 0.0 or Days Sales Outstanding of 12.22. DNAPrint financial statements analysis is a perfect complement when working with DNAPrint Genomics Valuation or Volatility modules.
DNAPrint | Working Capital | Build AI portfolio with DNAPrint Stock |
Currently Active Assets on Macroaxis
When determining whether DNAPrint Genomics is a strong investment it is important to analyze DNAPrint Genomics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact DNAPrint Genomics' future performance. For an informed investment choice regarding DNAPrint Stock, refer to the following important reports:Check out the analysis of DNAPrint Genomics Correlation against competitors. For more detail on how to invest in DNAPrint Stock please use our How to Invest in DNAPrint Genomics guide.You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of DNAPrint Genomics. If investors know DNAPrint will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about DNAPrint Genomics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of DNAPrint Genomics is measured differently than its book value, which is the value of DNAPrint that is recorded on the company's balance sheet. Investors also form their own opinion of DNAPrint Genomics' value that differs from its market value or its book value, called intrinsic value, which is DNAPrint Genomics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because DNAPrint Genomics' market value can be influenced by many factors that don't directly affect DNAPrint Genomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between DNAPrint Genomics' value and its price as these two are different measures arrived at by different means. Investors typically determine if DNAPrint Genomics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, DNAPrint Genomics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.